Abstract |
The management of women with recurrent and chronic vulvovaginal candidiasis continues to present a therapeutic challenge. In a prospective double-blind randomized study of 42 women with recurrent candidal vaginitis, clotrimazole 500-mg vaginal suppositories, administered once weekly for 2 weeks, induced clinical remission in 38 patients (90.4%) and achieved mycologic negative status in 83% of subjects. Thereafter, asymptomatic patients were randomized to receive monthly prophylactic vaginal tablets of clotrimazole 500 mg or placebo once a month. During the prophylactic phase, patients receiving placebo developed recurrences of symptomatic candida vaginitis at an extremely high rate, such that only one-third remained asymptomatic at the end of 6 months. In comparison, patients receiving clotrimazole demonstrated moderate protection from recurrence; which was maximal and statistically significant during the first 3 months of prophylaxis only (P less than .05). During the prophylactic period overall, attack rates were reduced by one-third with clotrimazole. No adverse reactions were observed with the administration of clotrimazole. In summary, clotrimazole therapy was successful in inducing an initial therapeutic response, but achieved only a modest long-term protective effect. Additional clinical benefit may be possible with more frequent clotrimazole prophylactic administration.
|
Authors | J D Sobel, C Schmitt, C Meriwether |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 73
Issue 3 Pt 1
Pg. 330-4
(Mar 1989)
ISSN: 0029-7844 [Print] United States |
PMID | 2644595
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Adult
- Candidiasis, Vulvovaginal
(drug therapy, prevention & control)
- Chronic Disease
- Clinical Trials as Topic
- Clotrimazole
(administration & dosage, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Imidazoles
(therapeutic use)
- Pessaries
- Prospective Studies
- Random Allocation
- Recurrence
|